BMY Extends Admilparant Program, Reinforcing Its Bet on Pulmonary Fibrosis
Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bristol-Myers Squibb (BMY) has launched a long-term extension study called “An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis.” The goal is to track long-term safety in patients with pulmonary fibrosis who finished earlier Admilparant trials, a key step before broader commercial use.
The study tests Admilparant, also known as BMS-986278, an oral drug designed to treat pulmonary fibrosis. The focus is on whether patients can stay on the drug safely over extended periods while managing this serious chronic lung disease.
This is an interventional Phase 3 study with a single treatment group, meaning all participants receive Admilparant rather than being split into drug and placebo arms. It is open-label, so both doctors and patients know they are getting the drug, and the main goal is treatment rather than prevention or diagnosis.
The trial is listed as “Not yet recruiting,” with initial submission on 25 Feb 2026, marking the formal plan to start. The latest update on 03 Apr 2026 signals that the protocol is current, while primary and final completion dates are not yet posted, showing the program is still in the setup phase.
For investors, this update confirms BMY’s continued push into lung disease, a large and underserved market that could add a new long-term revenue stream if data remain positive. It also keeps BMY in the race with other fibrosis players such as Roche and Boehringer Ingelheim, and may support sentiment that BMY is diversifying beyond oncology and immunology.
The Admilparant extension study is active in its setup and recently updated, with more details and ongoing changes available on the ClinicalTrials portal.
To learn more about BMY’s potential, visit the Bristol-Myers Squibb Company drug pipeline page.
